Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer

Vijay Patil, Vanita Noronha, Amit Joshi, Anuradha Chougule, Sadhana Kannan, Atanu Bhattacharjee, Supriya Goud, Sucheta More, Arun Chandrasekharan, Nandini Menon, Sujay Srinivas, Dilip Harindran Vallathol, Hollis Dsouza, Swaratika Majumdar, Sudeep Das, Abhinav Zawar, Satvik Khaddar, Amit Kumar, Gunjesh Singh, Kanteti Aditya Pavan Kumar, Rahul Ravind, Vaishakhi Trivedi, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash

Abstract

Background: Prolonged infusion of low dose gemcitabine (PLDG) in combination with platinum has shown promising activity in terms of improved response rate and progression free survival (PFS); especially in squamous non-small cell lung cancer (NSCLC). Hence, we conducted a phase 3 randomized non-inferiority study with the primary objective of comparing the overall survival (OS) between PLDG and standard dose of gemcitabine with platinum.

Methodology: Adult subjects (age ≥ 18 years), with stages IIIB–IV, NSCLC (squamous) and ECOG performance status of ≤ 2 were randomized 1:1 into either carboplatin with standard dose gemcitabine (1000 mg/m² intravenous over 30 min, days 1 and 8) (STD-G arm) or carboplatin along with low dose gemcitabine (250 mg/m² intravenous over 6 h, days 1 and 8) (LOW-G arm) for a maximum of 6 cycles. Tumor response was assessed by RECIST criteria version 1.1 every 2 cycles till 6th cycle and thereafter at 2 monthly intervals till progression. The primary endpoint was overall survival. 308 patients were randomized, 155 in STD-G arm and 153 in LOW-G arm, respectively.

Results: The median overall survival in STD-G arm was 6.8 months (95%CI 5.3–8.5) versus 8.4 months (95%CI 7–10.3) in the LOW-G arm (HR-0.890 (90%CI 0.725–1.092). The results with per protocol analysis were in line with these results. There was no statistical difference in progression free survival (HR-0.949; 90%CI 0.867–1.280) and adverse event rate between the 2 arms.

Conclusion: This study suggests that PLDG is an alternative to the standard gemcitabine schedule in squamous NSCLC, and either of these can be selected subject to patient convenience.

Keywords: Gemcitabine, Low dose, Prolonged infusion, Squamous cell cancer, NSCLC

1. Introduction

There has been a deluge of new targeted systemic therapies (Bevacizumab, Erlotinib, Gefitinib, Aftatinib, Osimertinib, Crizotinib, Alectinib, etc.) approved in non-small cell lung cancer (NSCLC) over the last 2 decades [1]. However, to a large extent, these targeted therapies are mostly applicable in non-squamous histologies which exhibit relevant driver mutations. As opposed to this, platinum-based doublet chemotherapy has been the backbone of systemic treatment for squamous NSCLC in the last few decades [1–4]. Gemcitabine with a platinum (either cisplatin or carboplatin) is preferred in squamous cell histology [5–7].

Gemcitabine has been used in 3 distinct schedules depending on infusion rates. The standard schedule of 1000–1200 mg/m² administered...
over 30 min (at a rate of 40 mg/m$^2$/min), moderately prolonged schedule of 1000 mg/m$^2$ over 100 min (at a rate of 10 mg/m$^2$/min) and the prolonged low dose schedule–gemcitabine (PLDG) of 250 mg/m$^2$ infused over 6 h (at a rate of 0.69 mg/m$^2$/min) [8]. The enzyme deoxycytidine kinase is the rate-limiting enzyme for gemcitabine activation. The pharmacological basis for using the prolonged low dose schedule is that this enzyme gets saturated at the low dose level [9,10]. PLDG has shown significant activity in several solid tumors including lung cancer [11]. In a phase 2 study by Zwitter et al., a response rate (RR) of 46%, with median progression free survival (PFS) of 6 months and 1 year overall survival (OS) of 40% was observed with PLDG [12]. In another study published by the same group, an apparent numerically superior activity and lower toxicity compared to the standard dose gemcitabine was reported [13]. Multiple phase 2 studies (at the time of planning this study) with PLDG echoed these findings of superior to similar activity in comparison with standard dose of gemcitabine [14,15].

In light of literature suggesting similar or better efficacy of PLDG and additional advantage of lowering the requirement of gemcitabine by approximately 75%, we decided to conduct a phase 3 randomized non-inferiority study with the primary objective of comparing the OS between low dose and standard dose gemcitabine, combined with platinum in advanced squamous NSCLC.

2. Methods

2.1. Study Conduct and Design

The study protocol was approved by the Institutional Ethics Committee and registered with the Clinical Trial Registry of India (CTRI/2013/02/003422). All patients provided written informed consent prior to participation in the study. The study was conducted in compliance with the Indian council of Medical research (ICMR) statement on human experimentation, the Declaration of Helsinki and the International Committee of Harmonisation (ICH) Harmonised Tripartite Guidelines for Good Clinical Practice (GCP). The study was funded by grants from Indian Cooperative Oncology Network (ICON). This was a phase 3, randomized, parallel group, non-inferiority study. The study recruited patients between 3rd May 2013 to 12th March 2018 and the data was censored for analysis on 6th October 2018.

2.2. Participants

Patients included in the study were adults (≥18 years of age), stages IIIb–IV (according to the AJCC/UICC staging system–7th edition) [16], pathologically proven chemotherapy-naive NSCLC (squamous), planned for first-line palliative chemotherapy. Eastern Cooperative Oncology Group Performance status (ECOG PS) 0–2 and with adequate organ function. Patients with symptomatic brain metastasis, superior vena cava obstruction, uncontrolled comorbidities or any other malignancy within the last 5 years were excluded from the study.

2.3. Interventions

Patients were randomly allocated to gemcitabine–carboplatin doublet schedule of either standard dose gemcitabine–carboplatin (STD-G arm) or the low dose gemcitabine–carboplatin (LOW-G arm). The dose of gemcitabine in STD-G arm was 1000 mg/m$^2$ infused in 0.9% normal saline over 30 min on day 1 and day 8 of a 21 day cycle. The dose of gemcitabine in LOW-G arm was 250 mg/m$^2$ infused in 0.9% normal saline over 6 h on day 1 and day 8 of a 21 day cycle. Carboplatin was administered at area under the curve (AUC) of 5 mg per millilitre per minute in 5% dextrose (unless patient was diabetic, in which case it was administered in 0.9% normal saline) over 1 h on day 1 of the 21 day cycle. The creatinine clearance was calculated according to the Cockcroft–Gault (CG) formula, for calculation of carboplatin dose. Prior to chemotherapy, patients received moderate emetogenic anti-emetic prophylaxis consisting of 5HT3 inhibitor and dexamethasone in both arms. Patients received a maximum of 6 cycles of chemotherapy in each arm if no progression was documented prior. Patients underwent contrast-enhanced computed tomography scan of the thorax and upper abdomen at baseline and after every 2 cycles of chemotherapy. Other imaging was also allowed, if indicated by patients’ symptoms. Tumor response was assessed by RECIST criteria version 1.1 [17]. After completion of 6 cycles of treatment, scans were done every 2 months until progression. Patients were followed up till death. Adverse events were captured at each clinical visit and assessed according to NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3 and managed accordingly. Dose reductions of chemotherapy according to adverse events were done in accordance with the study protocol.

Research in context

Evidence before this study

Gemcitabine and platinum chemotherapy (either cisplatin or carboplatin) is the standard of care and preferred regimen for the treatment of patients with advanced (stages III–IVB) squamous non-small cell lung cancer (NSCLC). Gemcitabine is delivered in the traditional schedule in this regimen of 1000 mg/m$^2$ within 30 min. A PubMed search was performed using the terms (Lung Cancer) AND ((Prolonged low dose infusion) AND Gemcitabine in March 2019. Multiple small phase 2 studies and meta analysis in NSCLC had evaluated prolonged low dose gemcitabine of 250 mg/m$^2$ given over 6 h (PLDG) and it seemed that it had similar or better efficacy than the traditional schedule. Some reports also suggested that the regimen had lower rates of adverse events. However, the evidence was of low quality and at best was regarded as hypothesis generating. We found not a single phase 3 randomized study present comparing the traditional schedule with the PLDG in NSCLC and so we planned this study.

Added value of this study

We report the results of a phase 3 randomized study testing the above hypothesis with 1:1 randomization of patients between standard schedule of gemcitabine and low dose prolonged infusion schedule of gemcitabine, both with carboplatin. The primary endpoint was overall survival. The median overall survival was similar between both arms and the hazard ratio on intent to treat analysis was 0.89 (90%CI 0.725–1.092). The confidence interval was within the limit of non-inferiority. The results with per protocol analysis were in concordance with these results. In addition, there was no statistical difference between the 2 arms in terms of response rate or progression free survival.

Implications of all the available evidence

On the basis of our report, PLDG (administered over 6 h) with carboplatin should be considered as an alternative to the standard of care schedule of 1000 mg/m$^2$ of gemcitabine administered within 30 min with carboplatin, as it leads to similar overall survival and progression free survival. In addition the PLDG has the advantage of decreasing requirement of gemcitabine and thus the cost of treatment by around 75%. The choice between the 2 schedules would depend upon the preferences of the patient and the treating physician as both regimens have equal efficacy and toxicity.
2.4. Endpoint

The primary endpoint was overall survival (OS), which was defined from date of randomization to date of death. Secondary endpoints were progression free survival (PFS), response rate (RR) and adverse event rate (AER). PFS was defined from date of randomization to date of progression or death, whichever was earlier. RR was defined as per RECIST version 1.1.

2.5. Sample Size

Non-inferiority was defined as an increase in the hazard of death (HR) \( < 1.33 \) in the experimental arm (LOW-G arm), as compared with the standard arm (STD-G arm). One year survival of \( \geq 33\% \) [18] and 23% was assumed in the standard arm and experimental arm, respectively. As the nature of treatment was palliative, a slight, non-marginal increase in the risk of death was considered clinically non-significant and could be offset by a decrease in toxicity or cost. Assuming a type 2 error of 20%, with a one sided type I error of 5%, equal allocation between both arms, accrual over 2 years and a study duration of 4 years, we required 220 events and sample size of 308 patients [19].

2.6. Randomization and Blinding

Simple randomization was done by a 3rd person (SK). The request for randomization was sent by the trial coordinator and the randomization arm was received online. The study was open label and hence both patients and treating physicians were aware of the study arms.

2.7. Statistical Methods

The final analysis was planned after the 220th event was observed. RStudio version 1.0.136 (RStudio Team (2016). RStudio: Integrated Development for R. RStudio, Inc., Boston, MA URL http://www.rstudio.

Fig. 1. Consort diagram. STD-G arm — standard dose gemcitabine with carboplatin arm. LOW-G arm — low dose gemcitabine with carboplatin arm.
com/) and SPSS version 20 (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp) were used for analysis. Intention to treat analysis was performed. Kaplan–Meier method was used for the estimation of the probability of OS and PFS in each arm. The median estimates of OS and PFS in each arm with their respective 95% confidence interval (CI) were reported. Brookmeyer and Crowley method was used for the construction of the 95%CI for the median. A non-inferiority p-value of 0.05 was considered as significant. The hazard ratio (HR) with its 90%CI interval was calculated using the COX regression analysis with Efron’s method of tie handling, with STD-G arm being considered as reference. The assumptions of proportional hazard model were checked using Schoenfeld residuals and assumptions were met. Per protocol analysis was also performed using above methodology to confirm the robustness of the results. To determine non-inferiority, the upper boundary of 90%CI of HR had to be below or equal to 1.33.

3. Results

3.1. Patients

Of the 308 patients randomized, 155 and 153 patients were randomized in STD-G arm and LOW-G arm respectively (Fig. 1, Consort diagram). Baseline characteristics were matched between both the arms (Table 1). The median follow-up was 20.6 months.

| Characteristics                  | Standard dose gemcitabine–carboplatin arm (n = 155) | Low dose gemcitabine–carboplatin arm (n = 153) |
|----------------------------------|-----------------------------------------------------|------------------------------------------------|
| Median age (interquartile range) | 61 (55–66)                                          | 59 (54–64)                                      |
| Age—no. (%)                     |                                                     |                                                 |
| Elderly (>65 years)             | 51 (32.9)                                           | 37 (24.2)                                       |
| Non elderly (<65 years)         | 104 (67.1)                                          | 116 (75.8)                                      |
| Gender—no. (%)                  |                                                     |                                                 |
| Male                             | 135 (87.1)                                          | 133 (86.9)                                      |
| Female                           | 20 (12.9%)                                          | 20 (13.1)                                       |
| ECOG PS—no. (%)                 |                                                     |                                                 |
| 0                                | 9 (5.8)                                             | 6 (3.9)                                         |
| 1                                | 137 (88.4)                                          | 138 (90.2)                                      |
| 2                                | 9 (5.8)                                             | 9 (5.9)                                         |
| Smoking—no. (%)                 |                                                     |                                                 |
| Yes                              | 124 (80.0)                                          | 118 (77.1)                                      |
| No                               | 31 (20.0)                                           | 35 (22.9)                                       |
| Histology—no. (%)               |                                                     |                                                 |
| Squamous                        | 141 (91.0)                                          | 147 (96.1)                                      |
| Squamous admixed with adenocarcinoma | 14 (9.0)                                     | 6 (3.9)                                         |
| Stage—no. (%)                   |                                                     |                                                 |
| IIIB                             | 37 (23.9)                                           | 28 (18.3)                                       |
| IV                               | 118 (76.1)                                          | 125 (81.7)                                      |
| Driver mutation status—no. (%)  |                                                     |                                                 |
| Absent or unknown                | 150 (96.8)                                          | 142 (92.8)                                      |
| EGFR sensitizing mutation       | 4 (2.6)                                             | 8 (5.2)                                         |
| ALK translocation                | 1 (0.6)                                             | 3 (2.0)                                         |
| Brain metastasis—no. (%)        |                                                     |                                                 |
| Yes                              | 9 (5.8)                                             | 14 (9.2)                                        |
| No                               | 146 (94.2)                                          | 139 (90.8)                                      |
| Radiation for brain metastasis—no. (%) | 8 (5.2)                      | 12 (7.8)                                        |
| Yes                              | 147 (94.8)                                          | 141 (92.2)                                      |
| No                               | 20 (12.9)                                           | 16 (10.5)                                       |
| Radiation for bone metastasis—no. (%) | 135 (87.1)                                 | 137 (89.5)                                      |

* 27 patients in each arm had received palliative radiation prior to enrollment.

3.2. Overall Survival

At data cutoff, 131 and 127 patients had died in STD-G and LOW-G arms, respectively. The median overall survival in STD-G arm was 6.8 months (95%CI 5.3–8.5) versus 8.4 days (95%CI 7–10.3) in LOW-G arm (Fig. 2). The hazard ratio for death was 0.890 (90%CI 0.725–1.092). The upper limit of 90%CI of hazard ratio was 1.092, which was below the acceptable non-inferiority margin of 1.33. The 1 year and 2 year overall survival in STD-G and LOW-G arm were 29.9% (95%CI 22.7–37.4) versus 33.1% (95%CI 25.6–40.8) and 7.8% (95%CI 3.5–14.4) versus 8.6% (95%CI 3.9–15.7). The p value for non-inferiority was 0.006. The results were consistent across all subgroups tested (Fig. 2).

The per protocol analysis for OS was performed in 296 patients (Fig. 1), 147 in STD-G arm and 149 in LOW-G arm. At the data cutoff, 124 patients had died in each of the arms. The results were in alignment with intention to treat analysis results (Fig. 3). The details of intent to treat, per protocol analysis and cause of death are shown in the Supplementary appendix (Tables 1S and 2S).

3.3. Progression Free Survival

At the data cutoff, 142 and 147 patients had progressed or died as first event in STD-G and LOW-G arm, respectively. The median progression free survival in STD-G arm was 3.1 months (95%CI 2.7–4.1) versus 4 months (95%CI 3.1–4.6) in LOW-G arm (Fig. 1S). The hazard ratio...
for progression was 0.949 (90% CI 0.867–1.280). The other details of intent to treat analysis and per protocol analysis for PFS are shown in the Supplementary appendix. The per protocol analysis for PFS was in concordance with the intent to treat analysis (Table 3S). The details of overall response rate in accordance with intention to treat and per protocol analysis are shown in Table 4S.

3.4. Compliance With Treatment

Out of the 153 patients allocated to STD-G arm, 147 patients (94.8%) took at least 1 cycle of treatment. The median number of cycles of gemcitabine and carboplatin received were 3 (IQR 2–6) and 3 (IQR 2–6), respectively. Six cycles of treatment were completed by 53 patients (34.2%). Progression of disease was the commonest reason for discontinuation of chemotherapy (n = 71 (45.8%)). The other reasons are shown in the Supplementary appendix in Table 5S. Number of patients who required gemcitabine and carboplatin dose reduction were 3 (IQR 2–6) respectively. The median average relative dose intensity for the STD-G arm was 0.92 (0.77–1). The details of second line treatment are shown in Table 6S.

Out of the 155 patients allocated to LOW-G arm, 149 patients (97.4%) took at least 1 cycle of treatment. The median number of cycles of gemcitabine and carboplatin received were 4 (IQR 2–6) and 4 (IQR 2–6) respectively. Six cycles of treatment were completed by 57 patients (37.3%). Progression of disease was the commonest reason for not completing 6 cycles (n = 64 (41.8%)). The other reasons for incompletion are shown in the Supplementary appendix. Number of patients who required gemcitabine and carboplatin dose reduction were 40 (26.1%) and 19 (12.4%), respectively. The median average relative dose intensity for the LOW-G arm was 0.92 (0.8–1). There was no statistical difference in any of the compliance parameters between the 2 arms (Table 5S). Second line therapy was received by 81 patients, details are shown in Table 6S.

3.5. Safety

There was no statistical difference in adverse events between both arms. Grade 3 or above myelosuppression was seen in 73 patients (54.5%) in the STD-G arm versus 78 patients (56.9%) in the LOW-G arm (p = 0.7147). Grade 3 or above liver function derangement was seen in 5 patients (3.7%) in the STD-G arm versus 11 patients (8%) in the LOW-G arm (p = 0.1968). Death due to adverse events was seen in 3 patients and all three were in the LOW-G arm (p = 0.2473). The toxicity leading to death in these 3 patients was pneumonia leading to sepsis (n = 1), diarrhoea leading to sepsis (n = 1) and non ST elevated myocardial infarction (n = 1). Out of the 3 deaths, only one death was attributable to the treatment but not related to trial participation. This patient had febrile neutropenia, diarrhoea and sepsis on day eight of cycle 1 to which he succumbed (Table 2).

4. Discussion

To our knowledge this is the first phase 3 randomized study addressing the issue of dose schedule with gemcitabine. Our results clarify that low dose gemcitabine in combination with carboplatin is non-inferior to standard dose gemcitabine with carboplatin in squamous cell NSCLC as first line palliative therapy. The median OS, 1 year OS, 2 year OS, PFS and response rates were similar in both arms. In fact the results were numerically superior in favor of low dose gemcitabine though not statistically superior in favor of low dose gemcitabine though not.

| Table 2 | Adverse events as per NCI-CTCAE version 3.0 till the date of data cutoff 6th October 2018. Adverse events which are occurred multiply are accounted as single and are represented by the highest grade of occurrence. |
|---------|---------------------------------------------------------------------------------------------------------|
| Adverse event | Standard dose gemcitabine–carboplatin arm (n = 134) | Low dose gemcitabine–carboplatin arm (n = 137) |
| | Any grade | Grades 3–5 | Any grade | Grades 3–5 |
| Anemia | 126 (94) | 43 (32.1) | 127 (92.7) | 47 (34.3) |
| Neutropenia | 71 (53) | 38 (28.4) | 75 (54.7) | 48 (35) |
| Thrombocytopenia | 64 (47.8) | 34 (25.4) | 61 (44.5) | 27 (19.7) |
| SGOT increase | 59 (44) | 5 (3.7) | 68 (49.6) | 8 (5.8) |
| SGPT increase | 69 (50.4) | 3 (2.2) | 61 (45.5) | 11 (8) |
| Bilirubin increase | 7 (3.2) | – | 5 (3.6) | – |
| Creatinine increase | 11 (8.2) | 1 (0.7) | 7 (5.1) | – |
| Hypokalemia | 59 (39.3) | 43 (32.1) | 114 (83.2) | 51 (37.2) |
| Hyperkalemia | 1 (0.7) | – | 1 (0.7) | – |
| Hypercalcemia | 18 (13.4) | – | 14 (10.2) | – |
| Hyponatremia | 22 (16.4) | 3 (2.2) | 31 (22.6) | 4 (2.9) |
| Hypernatremia | 30 (22.4) | 1 (0.7) | 30 (21.9) | 3 (2.2) |
| Hypomagnesaemia | 30 (22.4) | 1 (0.7) | 62 (45.3) | – |
| Hypomagnesaemia | 4 (3) | – | 3 (2.2) | 1 (0.7) |
| Hypocalcemia | 14 (10.4) | – | 15 (10.9) | 1 (0.7) |
| Fatigue | 75 (56) | 13 (9.7) | 91 (66.4) | 19 (13.9) |
| Oral mucositis | 9 (6.7) | – | 14 (10.2) | 2 (1.5) |
| Rash—maculopapular | 11 (8.2) | – | 8 (5.8) | – |
| Fever | 48 (35.8) | 1 (0.7) | 65 (47.4) | 3 (2.2) |
| Diarrhoea | 32 (23.9) | 10 (7.5) | 45 (32.8) | 10 (7.3) |
| Vomiting | 24 (17.8) | 4 (3) | 31 (22.6) | 2 (1.5) |
| Pneumonia | 11 (8.2) | 8 (6) | 15 (10.9) | 14 (10.2) |

**Fig. 3.** Overall survival in the per protocol population. Panel A shows the survival curves estimated by Kaplan–Meier method. Panel B shows the forest plot, depicting the impact of treatment on various subgroups. Data is as of 6th October 2018 (the date of data cutoff).
itself, a decrement in dose from 1000 mg/m² to 250 mg/m² will de-
sult in low and middle income countries is limited [33,34]. Thus, these re-
sults have implications in such economically underprivileged countries.

The current NCCN guidelines recommend treatment with systemic
chemotherapy if driver mutation status (EGFR, ALK, ROS-1, BRAF) is
negative or unknown and PD-L1 expression is below 50% in squamous
cell NSCLC requiring palliative systemic therapy [11]. The cumulative in-
creased incidence of these mutations status is in the range of 10–15%
[25,26] and PD-L1 expression above 50% is seen in 18% of patients
[27–32]. Hence, despite recent advances in the treatment of NSCLC,
majority of the patients (>50%) are only eligible for systemic chemo-
therapy. Further, the access to targeted therapies and immunotherapy
in low and middle income countries is limited [33,34]. Thus, these re-
sults have implications in such economically underprivileged countries.

The current study too, approved immunotherapy agents where received
by less than 5% of eligible patients (Table 6S) and thus lowering the
OS.

These results also have financial implications. On crude calculation
itself, a decrement in dose from 1000 mg/m² to 250 mg/m² will de-
crease the cost of treatment with gemcitabine by 75% per dosing. As of
March 2019, cost of 1 g of Gemzar was 782.05 USD and 200 mg was
163.21 USD [35]. Assuming a body surface area of 1.8, this would allow
the amount to change difference 945.26 USD per dosing and per cycle cost
difference of 1890.52 USD for gemcitabine. However, the cost of admin-
istration for longer duration needs to be accounted in this calculation,
especially in those countries where longer duration of administration
of chemotherapy is charged higher. However, in the PI’s institute and
in the majority of low and middle income countries the cost of chemo-
therapy is far larger than its administration [36]. A detailed financial
analysis, however, was not performed in the study and hence the lowered
costs of chemotherapy need to be balanced against the incon-
venience and cost of administration of PLDG. PLDG requires 6 h of
gemcitabine infusion against 30 min in the standard schedule which might necessitate the use of a central line.

Our study is not without its limitations. The study randomiza-
tion was not stratified and it was a single centre study. However,
there was no apparent difference in baseline characteristics of the
2 arms. Being a single centre study, the quality checks and uniform-
ity was easily maintained during the study. The chemotherapy and
supportive care protocols used were standard and thus general-
izable. Another important limitation was the lack of prespecified
cost effective analysis.

However, despite these limitations, the results of this large phase 3
randomized study suggest that low dose prolonged gemcitabine infusion is an alternative to the standard gemcitabine schedule. It pro-
duces similar OS, PFS and ORR without an increase in the adverse
event rate.

**Conflict of Interest**

None declared.

**Author Contributions**

1. Dr. Vijay Patil — literature search, figures, study design, study imple-
mentation, data collection, data analysis, data interpretation, writ-
ing, final approval.
2. Dr. Vanita Noronha — literature search, study design, study imple-
mentation, data interpretation, writing, final approval.
3. Dr. Amit Joshi — study design, study implementation, data inter-
pretation, writing, final approval.
4. Dr. Anuradha Chougule — study implementation, data interpreta-
tion, final approval.
5. Mrs. Sadhana Kanan — study implementation, data interpretation,
final approval.
6. Dr. Atanu Bhattacharjee — data analysis, data interpretation, writ-
ing, final approval.
7. Dr. Supriya Goud — study implementation, data interpretation, final
approval.
8. Dr. Sucheta More — study implementation, data interpretation, final
approval.
9. Dr. Arun Chandrasekharan — study implementation, data collection,
final approval.
10. Dr. Nandini Menon — study implementation, data collection, final
approval.
11. Dr. Sujay Srinivas — study implementation, data collection, final
approval.
12. Dr. Dilip Harindran Vallathol — study implementation, data collec-
tion, final approval.
13. Dr. Hollis Dsouza — study implementation, data collection, final
approval.
14. Dr. Swaratika Majumdar — study implementation, data collection,
final approval.
15. Dr. Sudeep Das — study implementation, data collection, final
approval.
16. Dr. Abhinav Zawar — study implementation, data collection, final
approval.
17. Dr. Satvik Khaddar — study implementation, data collection, final
approval.
18. Dr. Amit Kumar — study implementation, data collection, final
approval.
19. Dr. Gunjesh Singh — study implementation, data collection, final
approval.
20. Dr. Kanteti Aditya Pavan Kumar — study implementation, data col-
lection, final approval.
21. Dr. Rahul Ravind — study implementation, data collection, final
approval.
22. Mrs. Vaishakh Trivedi — study implementation, data interpreta-
tion, final approval.
23. Mrs. Vichitra Behel — study implementation, data interpreta-
tion, final approval.
24. Dr. Abhishek Mahajan — study implementation, data interpreta-
tion, final approval.
25. Dr. Amit Janu — study implementation, data interpretation, final
approval.
26. Dr. Nilendu Purandare — study implementation, data interpreta-
tion, final approval.
27. Dr. Kumar Prabhash — literature search, figures, study design, study
implementation, data collection, data analysis, data interpretation,
writing, final approval and administrative support.
Acknowledgements/Funding

The study was funded by grants from Indian Cooperative Oncology Group (ICON). The funders had no role in study design, data collection, data analysis, interpretation, writing of the paper or decision of submitting the manuscript for publication.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.eclinm.2019.03.011.

References

[1] Ettinger DS, Aisner DL, Wood DE, et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw 2018;16:807–21.
[2] Ettinger DS, Akerley W, Borghaei H, et al. Non–small cell lung cancer, version 2.2013. J Natl Compr Canc Netw 2013;11:645–53.
[3] Berger MJ, Ettinger DS, Aston J, et al. NCCN guidelines insights: antiemesis, version 2.2017. J Natl Compr Canc Netw 2017;15:883–93.
[4] Novello S, Barlesi F, Caffo O, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v1–27.
[5] Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543–51.
[6] Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ, Whittle J. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. J Thorac Oncol 2014;9:702–9.
[7] de Castris TB, da Silva EMK, Gois AFT, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev 2013(8):1–59.
[8] Veerman G, Ruiz van Hapener VW, Vermorken JB, et al. Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996;38:335–42.
[9] Grunewald R, Kastritsis H, Keating MJ, Schellens JHM. Prolonged versus standard gemcitabine in fusion: translation of molecular pharmacology to new treatment strategy. Oncol 2008;13:261–76.
[10] Veerman G, Ruiz van Hapener VW, Vermorken JB, et al. Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996;38:335–42.
[11] Zwitter M, Kovac V, Rajer M, Vrankar M, Smrdel U. Two schedules of chemotherapy for patients with advanced-stage non-small-cell lung cancer. Urol Oncol 2008;26:133–6.
[12] Zhang M, Li G, Wang Y, et al. PD-L1 expression in lung cancer and its correlation to clinicopathological features. Oncol Lett 2017;14:545–50.
[13] Zhang M, Wang D, Sun Q, et al. Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma. Oncotarget 2017;8:51630–40.
[14] Guo Q, Sun Y, Yu S, et al. Programmed cell death-ligand 1 expression in advanced non-small-cell lung cancer patients with driver mutations: a meta-analysis. Sci Rep 2017;7:10255.
[15] Horten S, Gavreault GL. Cancer in low- and middle-income countries: an economic overview. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer: control and development. The World Bank; 2016.
[16] Drugs.com. Gemzar prices, coupons & patient assistance programs. Drugs.comhttps://www.drugs.com/price-guide/gemzar, Accessed date: 7 March 2019.
[17] User S. Schedule of charges. Tata Memorial Hospitalhttps://tmc.gov.in/TMH/index.php/schedule-of-charges, Accessed date: 18 October 2018.